BE of parenterals [Regulatives / Guidelines]

posted by Helmut Homepage – Vienna, Austria, 2018-10-08 13:53 (2464 d 09:00 ago) – Posting: # 19416
Views: 4,269

Hi Varsha,

❝ As per guideline we need not to perform any Bioequivalence studies for Injectables.


It’s not that simple. See e.g., the EMA’s GL page 23.

❝ But Enoxaparin sodium being a biologically derived product, is there any need of performing the BA-BE studies.


That’s not the point. See the FDA’s guidance for conditions whether the in vivo PD (!) study can be waived.

❝ Does the guideline differs for a biologically derived product?


Differ to what? To get an idea, see the EMA’s guidelines on biosimilars.

Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

UA Flag
Activity
 Admin contact
23,428 posts in 4,929 threads, 1,686 registered users;
82 visitors (0 registered, 82 guests [including 16 identified bots]).
Forum time: 22:54 CEST (Europe/Vienna)

No matter what side of the argument you are on,
you always find people on your side
that you wish were on the other.    Thomas Berger

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5